David Roblin (Relation)
June 9, 2022 06:16 AM EDTUpdated 06:50 AM
Financing
Startups
AI

Ex­clu­sive: Pfiz­er vet grabs $25M seed round to 'in­te­grate' ma­chine learn­ing, ge­nomics tech in drug R&D

Amber Tong

Hav­ing been in­volved in a num­ber of at­tri­tion task force ef­forts dur­ing his tenure as Eu­ro­pean R&D chief at Pfiz­er, David Rob­lin tells me there’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

It's been three months with­out a biotech IPO

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times